In our study, we aimed to evaluate the clinical, biochemical, hematological, and genetic parameters that may be associated with subclinical inflammation in FMF patients (with amyloidosis and without amyloidosis) receiving IL-1 antagonist therapy. Here, IL1A is linked to amyloidosis.